Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DAP000311

Drug Information
SynonymsPDSP2_001042; Cloxazepine; 1977-10-2; 27833-64-3 (succinate); BSPBio_003479; Lopac0_000720; C18H18ClN3O; KBio2_003403; L001085; QTL1_000050; HF 3170; Oxilapine; HSDB 3111; BRN 0626753; Loxitane IM; 54810-23-0 (mono-hydrochloride); Loxapine (USAN/INN); Prestwick3_000132; SUM-3170; PDSP1_001058; SPBio_001814; Dibenzacepin; NCGC00021145-01; 2-Chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine; LW 3170; Dibenz[b,f][1,4]oxazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-; Spectrum_000355; CHEMBL831; Loxapinum; Loxapinum [INN-Latin]; KBio2_005971; Spectrum2_001737; C07104; Loxapine [USAN:INN:BAN]; KBio3_002983; KBioSS_000835; Loxapine [USAN:BAN:INN]; CL-71,563; EINECS 217-835-3; CHEBI:50841; MolPort-002-885-838; NCGC00022279-04; Loxapina [INN-Spanish]; UNII-LER583670J; NCGC00022279-03; 2-Chloro-11-(4-methyl-1-piperazinyl)-dibenz(b,f)(1,4)oxazepine; KBio2_000835; BPBio1_000226; 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine; HF3170; SUM 3170; CL-62362; Prestwick1_000132; SPBio_002143; Lossapina [DCIT]; SpecPlus_000823; Prestwick2_000132; S-805; CID3964; 2-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine; Spectrum3_001830; NCGC00022279-05; Hydrofluoride 3170; Loxapinsuccinate; DivK1c_006919; LS-61562; 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,5]benzoxazepine; loxapine; AC1L1H3Z; AC1Q3ZWR; Lossapina; Dibenzoazepine; Spectrum5_001857; CL 62362; Loxapin; Dibenz(b,f)(1,4)oxazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-; DB00408; BRD-K39915878-036-04-6; ZINC19796158; NCGC00021145-07; D02340; 2-Chloro-11-(4-methylpiperazino)dibenzo(b,f)(1,4)oxazepine; BRD-K39915878-036-05-3; KBio1_001863; Loxepine; S 805; Prestwick0_000132; BSPBio_000204; Loxapina    
Trade NameLoxapac; Loxitane    
CompanyWatson Laboratories    
IndicationPsychotic disordersApproved    [1]

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Therapeutic ClassAntipsychotic Agents    
CAS NumberCAS 1977-10-2
PubChem Compound IDCID 3964.    
PubChem Substance IDSID 9315.    
SuperDrug ATC IDN05AH01;    
SuperDrug CAS ID001977102;    
TargetD(2) dopamine receptorAntagonist[2]
Ref 1FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 076762 To Reference
Ref 2Remoxipride in Parkinson's disease: differential response in patients with dyskinesias fluctuations versus psychosis. Clin Neuropharmacol. 1995 Feb;18(1):39-45. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543